Search alternatives:
point decrease » point increase (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 wt » 2 wt (Expand Search), 1 wt (Expand Search)
point decrease » point increase (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 wt » 2 wt (Expand Search), 1 wt (Expand Search)
-
981
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
982
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
983
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
984
-
985
-
986
-
987
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
988
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
989
-
990
-
991
-
992
-
993
-
994
-
995
-
996
-
997
-
998
-
999
-
1000